-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the American Cancer Society, ovarian cancer has become the fifth leading type of cancer death among women, with the majority of ovarian cancers classified as high-grade serous ovarian cancer (HGSOC)
Some scientists are considering using immunotherapy to overcome drug resistance
According to new research in the Proceedings of the National Academy of Sciences (PNAS), for immunotherapy to really work, it is necessary to address the protective environment that cancer cells create for themselves
It happens that CD155 itself can bind to the checkpoint receptor TIGIT on immune cells, and tumors indirectly control the activation state of immune cells through CD155
▲ Inhibiting FAK and reducing the level of CD155 are the prerequisites for improving the efficiency of immunotherapy (Image source: Reference [2], credit: UC San Diego Health Sciences)
In animal models, the researchers tried administering anti-FAK drugs to mice with ovarian cancer, and the mice started to drop levels of the protein CD155
Compared with controls, mice given both drugs had significantly smaller tumors and better survival rates
Note: The original text has been deleted
References:
[1] Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis, Proceedings of the National Academy of Sciences (2022).
[2] How ovarian cancer defies immunotherapy.
